U.S. flag

An official website of the United States government

NM_003106.4(SOX2):c.87_96dup (p.Asn33fs) AND Anophthalmia/microphthalmia-esophageal atresia syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Feb 8, 2019
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001253803.1

Allele description [Variation Report for NM_003106.4(SOX2):c.87_96dup (p.Asn33fs)]

NM_003106.4(SOX2):c.87_96dup (p.Asn33fs)

Genes:
LOC108281177:SOX2 5' regulatory region [Gene]
SOX2-OT:SOX2 overlapping transcript [Gene - OMIM - HGNC]
SOX2:SRY-box transcription factor 2 [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
3q26.33
Genomic location:
Preferred name:
NM_003106.4(SOX2):c.87_96dup (p.Asn33fs)
HGVS:
  • NC_000003.12:g.181712447_181712456dup
  • NG_009080.1:g.5514_5523dup
  • NM_003106.4:c.87_96dupMANE SELECT
  • NP_003097.1:p.Asn33fs
  • LRG_719t1:c.87_96dup
  • LRG_719:g.5514_5523dup
  • NC_000003.11:g.181430235_181430244dup
  • NM_003106.2:c.87_96dup
  • p.Asn33Glyfs*66
Protein change:
N33fs
Links:
dbSNP: rs1714839412
NCBI 1000 Genomes Browser:
rs1714839412
Molecular consequence:
  • NM_003106.4:c.87_96dup - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Name:
Anophthalmia/microphthalmia-esophageal atresia syndrome (MCOPS3)
Synonyms:
Microphthalmia syndromic 3; Microphthalmia and esophageal atresia syndrome; Anophthalmia clinical with associated anomalies; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0008799; MedGen: C1859773; Orphanet: 77298; OMIM: 206900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001427027Clinical Genomics Program, Stanford Medicine
no assertion criteria provided
Pathogenic
(Feb 8, 2019)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Clinical Genomics Program, Stanford Medicine, SCV001427027.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providedclinical testingnot provided

Description

The p.Asn33Glyfs*66 variant in the SOX2 gene was identified de novo in this individual and has been previously reported as de novo in a 28 weeks gestation fetus with bilateral anophthalmia (Chassaing et al., 2014). This variant results in a 10bp duplication, which causes a shift in the protein reading frame leading to a premature termination codon 66 amino acids downstream. Although nonsense-mediated decay is not predicted to occur, the truncated protein is expected to result in loss-of-function. Heterozygous loss-of-function is an established mechanism of disease for the SOX2 gene. This variant was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). However, the ability to detect large insertion/deletion variants is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, there is sufficient evidence to classify the p.Asn33Glyfs*66 variant as pathogenic for autosomal dominant SOX2-related eye disorders based on the information above. [ACMG evidence codes used: PVS1, PS2, PM2]

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 26, 2023